| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/01/2023 | 241.61% | Cantor Fitzgerald | $16 → $11 | Maintains | Overweight |
| 12/01/2022 | 552.17% | HC Wainwright & Co. | $22 → $21 | Maintains | Buy |
| 11/30/2022 | 459.01% | Oppenheimer | $26 → $18 | Maintains | Outperform |
| 09/20/2022 | 583.23% | HC Wainwright & Co. | $32 → $22 | Maintains | Buy |
| 03/07/2022 | 893.79% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 09/21/2021 | 831.68% | Oppenheimer | → $30 | Initiates Coverage On | → Outperform |
| 09/02/2021 | 1142.24% | B. Riley Securities | → $40 | Initiates Coverage On | → Buy |
| 08/19/2021 | 986.96% | Cantor Fitzgerald | → $35 | Initiates Coverage On | → Overweight |
What is the target price for Portage Biotech (PRTG)?
The latest price target for Portage Biotech (NASDAQ: PRTG) was reported by Cantor Fitzgerald on August 1, 2023. The analyst firm set a price target for $11.00 expecting PRTG to rise to within 12 months (a possible 241.61% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Portage Biotech (PRTG)?
The latest analyst rating for Portage Biotech (NASDAQ: PRTG) was provided by Cantor Fitzgerald, and Portage Biotech maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Portage Biotech (PRTG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Portage Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Portage Biotech was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.
Is the Analyst Rating Portage Biotech (PRTG) correct?
While ratings are subjective and will change, the latest Portage Biotech (PRTG) rating was a maintained with a price target of $16.00 to $11.00. The current price Portage Biotech (PRTG) is trading at is $3.22, which is out of the analyst's predicted range.